NeurAxis, Inc. Hits New 52-Week High of $6.60, Up 116.1%

NeurAxis, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 6.60 on March 10, 2026. This achievement marks a remarkable increase of 116.1% over the past year, significantly outperforming the S&P 500, which has seen a gain of 20.78% during the same period. With a market capitalization of USD 59 million, NeurAxis operates in a competitive industry characterized by rapid innovation and development. The company's financial metrics reflect its current position, with a price-to-book ratio of 25.78. However, it is important to note that NeurAxis is currently loss-making, as indicated by its negative P/E ratio and a return on equity of -330.30%. Additionally, the company has a debt-to-equity ratio of -1.80, suggesting a unique financial structure. The stock's previous 52-week low was recorded at USD 1.33, highlighting the significant upward movement in its price. This new high underscores NeurAxis's evolving market position within the biotechnology landscape.